Biomarin Pharmaceutical Stock (NASDAQ: BMRN)

Biomarin Pharmaceutical (NASDAQ:BMRN) Stock, Quote.Headers.trade-ideas

Biomarin Pharmaceutical

BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.

FedEx planes.

Large Cap

News

Movers

Trading Ideas

ASND

BMRN

BNTX

CHWY

KSPI

MUSA

RIVN

SMMT

10 large-cap stocks worst performers in last week: SMMT -23.61%, KSPI -21.66%, BMRN -16.74%, RIVN -13.26%, FDX -11.08%, BNTX -9.01%, AJG -7.17%, CHWY -6.97%, NVO -6.93%, MUSA -6.90%

Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?

Stock market analysts

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

ABNB

AGRO

DOCS

IMCR

MODG

PODD

GE Vernova To Rally Over 30%? Here Are 10 Top Analyst Forecasts For Tuesday

Analyst Color

Biotech

Health Care

General

BioMarin stock dips in response to TransCon CNP data, as analysts note TransCon CNP could challenge BioMarin&#39;s Voxzogo by late 2025 due to its dosing schedule and potential safety benefits.

Despite Being First Mover, BioMarin&#39;s Voxzogo For Dwarfism To Face Pressure From Ascendis&#39; Candidate In Near Term

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical Inc

Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) has outperformed the market over the past 20 years by 5.46% on an annualized basis producing an average annual return of 13.94%. Currently, Biomarin Pharmaceutical has a market capitalization of $13.44 billion. 
Buying $1000 In BMRN: If an investor had bought $1000 of BMRN stock 20 years ago, it would be worth $13,575.00 today based on a price of $70.59 for BMRN at the time of writing.
<h3>Biomarin Pharmaceutical's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727100012_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 20 Years Ago, You Would Have $14,000 Today

These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) stock declined 23.61%. The company announced that data for the novel, potential first-in-class investigational bispecific antibody, ivonescimab, was presented <a href="https://www.benzinga.com//node/40873837" target="_blank" rel="noreferrer noopener">at the 2024 ESMO Annual Meeting</a>.</li>
<li>Joint Stock Company Kaspi.kz (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KSPI#NASDAQ">KSPI</a>) stock tumbled 21.66% after Culper Research <a href="https://www.benzinga.com//node/40943334" target="_blank" rel="noreferrer noopener">issued a short report on the company</a>.</li>
<li>BioMarin Pharmaceutical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) stock lost 16.74% last week <a href="https://www.benzinga.com//node/40885653" target="_blank" rel="noreferrer noopener">following strong dwarfism drug data</a> from rival Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>).</li>
<li>Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) lost 13.26% <a href="https://www.benzinga.com//node/40961732" target="_blank" rel="noreferrer noopener">last week</a>.</li>
<li>FedEx Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) stock fell 11.08% after the company reported worse-than-expected Q1 financial results and <a href="https://www.benzinga.com//node/40948046" target="_blank" rel="noreferrer noopener">cut FY25 guidance</a>.</li>
<li>BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) stock decreased 9.01%. Pfizer, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and BioNTech received positive CHMP opinion for omicron KP.2-adapted <a href="https://www.benzinga.com//node/40956192" target="_blank" rel="noreferrer noopener">COVID-19 vaccine in the European Union</a>.</li>
<li>Arthur J. Gallagher &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>) stock fell 7.17%. Several analysts raised <a href="https://www.benzinga.com/quote/ajg/analyst-ratings" target="_blank" rel="noreferrer noopener">the price target on the stock</a>.</li>
<li>Chewy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) shares declined 6.97% after the company announced a selling stockholder&#8217;s public offering of shares <a href="https://www.benzinga.com//node/40949015" target="_blank" rel="noreferrer noopener">and a concurrent share repurchase</a>.</li>
<li>Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) stock fell 6.93% after <a href="https://www.benzinga.com//node/40961934" target="_blank" rel="noreferrer noopener">headline results from the mid-stage study</a> of monlunabant in obese patients.</li>
<li>Murphy USA Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUSA#NYSE">MUSA</a>) shares fell 6.90% after JP Morgan downgraded the stock from Neutral to Underweight but raised its <a href="https://www.benzinga.com/quote/musa/analyst-ratings" target="_blank" rel="noreferrer noopener">price target from $415 to $435</a>.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/09/40972008/constellation-energy-li-auto-and-carvana-are-among-top-11-large-cap-gainers-last-week-sept-16-sept" target="_blank" rel="noreferrer noopener">Constellation Energy, Li Auto And Carvana Are Among Top 11 Large Cap Gainers Last Week (Sept 16-Sept 20): Are The Others In Your Portfolio?</a></li>
</ul>
Photo via Shutterstock

Highlighting Improvements In Health-Related Quality Of Life, Bone Length, And Strength In Children With Achondroplasia And Other Genetic Skeletal Conditions

BioMarin To Present Positive VOXZOGO (Vosoritide) Data From CANOPY Clinical Program At 2024 International Skeletal Dysplasia Society Meeting

Scotiabank analyst George Farmer maintains Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Sector Perform and lowers the price target from $95 to $78.

Scotiabank Maintains Sector Perform on Biomarin Pharmaceutical, Lowers Price Target to $78

Truist Securities analyst Joon Lee maintains Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Buy and lowers the price target from $118 to $90.

Truist Securities Maintains Buy on Biomarin Pharmaceutical, Lowers Price Target to $90

Wells Fargo analyst Mohit Bansal maintains Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Overweight and lowers the price target from $115 to $90.

Wells Fargo Maintains Overweight on Biomarin Pharmaceutical, Lowers Price Target to $90

RBC Capital analyst Luca Issi maintains Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Sector Perform and lowers the price target from $100 to $85.

RBC Capital Maintains Sector Perform on Biomarin Pharmaceutical, Lowers Price Target to $85

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page.</a>
<ul>
<li>Needham cut the price target for Immunocore Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMCR#NASDAQ">IMCR</a>) from $81 to $78. Needham analyst Gil Blum maintained a Buy rating. Immunocore shares fell 1.6% to close at $33.00 on Monday. <a href="https://www.benzinga.com/quote/IMCR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird raised the price target for Doximity, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) from $41 to $45. Baird analyst Vikram Kesavabhotla maintained an Outperform rating. Doximity shares rose 0.3% to close at $39.44 on Monday. <a href="https://www.benzinga.com/quote/docs/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities boosted GE Vernova Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) price target from $200 to $300. B of A Securities analyst Andrew Obin upgraded the stock from Neutral to Buy. GE Vernova shares rose 1.9% to close at $229.93 on Monday. <a href="https://www.benzinga.com/quote/gev/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley cut Adecoagro S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGRO#NYSE">AGRO</a>) price target from $14.5 to $12.5. Morgan Stanley analyst Javier Martinez downgraded the stock from Overweight to Equal-Weight. Adecoagro shares fell 0.2% to close at $11.55 on Monday. <a href="https://www.benzinga.com/quote/agro/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Bernstein slashed the price target for Airbnb, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) from $174 to $155. Bernstein analyst Richard Clarke maintained an Outperform rating. Airbnb fell 0.2% to close at $117.55 on Monday. <a href="https://www.benzinga.com/quote/abnb/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler raised Insulet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) price target from $230 to $285. Piper Sandler analyst Matt O&#8217;Brien maintained an Overweight rating. Insulet shares rose 0.01% to close at $233.89 on Monday. <a href="https://www.benzinga.com/quote/podd/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stifel cut BioMarin Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) price target from $115 to $87. Stifel analyst Paul Matteis maintained a Buy rating. BioMarin Pharmaceutical shares fell 17.7% to close at $69.86 on Monday. <a href="https://www.benzinga.com/quote/bmrn/analyst-ratings">See how other analysts view this stock.</a></li>
<li>TD Cowen cut the price target for Topgolf Callaway Brands Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MODG#NYSE">MODG</a>) from $13 to $10. TD Cowen analyst John Kernan maintained a Hold rating. Topgolf Callaway Brands shares rose 2% to close at $10.40 on Monday. <a href="https://www.benzinga.com/quote/modg/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stifel slashed Jabil Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>) price target from $135 to $130. Stifel analyst Matthew Sheerin maintained a Buy rating. Jabil shares fell 0.2% to close at $105.72 on Monday. <a href="https://www.benzinga.com/quote/jbl/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B. Riley Securities raised Alcoa Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AA#NYSE">AA</a>) price target from $37 to $41. B. Riley Securities analyst Lucas Pipes maintained a Neutral rating. Alcoa shares rose 6.1% to close at $34.50 on Monday. <a href="https://www.benzinga.com/quote/aa/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying GEV stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="481" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/17085859/image-132-1024x481.png" alt="" class="wp-image-551787" style="width:592px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/17085859/image-132-1024x481.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/17085859/image-132-300x141.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/17085859/image-132-768x361.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/17085859/image-132.png 1322w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/40896687/how-to-earn-500-a-month-from-fedex-stock-ahead-of-q1-earnings">How To Earn $500 A Month From FedEx Stock Ahead Of Q1 Earnings</a></li>
</ul>

B of A Securities analyst Geoff Meacham maintains Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Buy and lowers the price target from $130 to $115.

B of A Securities Maintains Buy on Biomarin Pharmaceutical, Lowers Price Target to $115

Stifel analyst Paul Matteis maintains Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Buy and lowers the price target from $115 to $87.

Stifel Maintains Buy on Biomarin Pharmaceutical, Lowers Price Target to $87

Bernstein analyst William Pickering maintains Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Outperform and lowers the price target from $116 to $90.

Bernstein Maintains Outperform on Biomarin Pharmaceutical, Lowers Price Target to $90

Ascendis Pharma A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>)&nbsp;released topline data on Monday from a trial that included 84 children with achondroplasia, a genetic disorder that causes dwarfism and&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40882593/ascendis-pharmas-rare-dwarfism-candidate-shows-promise-in-trial-fda-submission-expected-next-year" rel="noreferrer noopener">disproportionate short stature</a>.
In the trial, children treated with once-weekly TransCon CNP demonstrated annualized growth velocity (AGV) superior to placebo.
BioMarin Pharmaceutical Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) stock is trading lower in reaction to the data <a href="https://www.benzinga.com/general/biotech/22/11/29694519/ascendis-pharmas-program-hits-primary-goal-in-children-with-short-limbed-dwarfism" target="_blank" rel="noreferrer noopener">from rival Ascendis</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40707614/rare-disease-focused-ascendis-pharma-stock-falls-on-underwhelming-q2-earnings-guidance-cut" rel="noreferrer noopener">Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut</a>.
William Blair notes that the efficacy of TransCon CNP is comparable to BioMarin&#8217;s Voxzogo (vosoritide), which is approved for promoting linear growth in children with achondroplasia and open growth plates (epiphyses).
Early data indicates that TransCon CNP could challenge Voxzogo&#8217;s market share by late 2025. Moreover, Ascendis&#8217; TransCon CNP stands out due to its once-weekly dosing schedule and potentially improved safety profile, making it a more appealing option.
The analyst adds, &#8220;We think Ascendis&#8217;s freedom to operate is still unclear given it may be at risk of infringing on BioMarin&#8217;s long-acting CNP patent portfolio, which could restrict Ascendis&#8217; launch or at the very least result in royalties to BioMarin.&#8221;
The William Blair analyst emphasizes BioMarin&#8217;s first-mover advantage, noting that the company is actively conducting additional trials to broaden Voxzogo&#8217;s label.
BioMarin also plans to submit an investigational new drug application for its long-acting CNP in the fourth quarter of 2024. However, competition from TransCon CNP is expected to place continued pressure on Voxzogo&#8217;s market share, which may weigh on the stock in the near future.
Earlier this month, BioMarin&nbsp;announced its&nbsp;plans to land $4 billion in&nbsp;revenue by 2027 and target an adjusted operating margin of <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40731810/biomarin-restructures-outlines-roadmap-to-4b-revenues-by-2027" rel="noreferrer noopener">low-to-mid 40</a> percent.
Price Action: BMRN stock is down 17.70% at $69.86 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40881407/back-to-back-fda-approvals-for-roches-two-under-the-skin-injections" target="_blank" rel="noreferrer noopener">Back-To-Back FDA Approvals For Roche&#8217;s Two Under-The-Skin Injections</a>.</li>
</ul>

Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term

WIIM

BioMarin Pharmaceutical shares are trading lower following strong dwarfism drug data from rival Ascendis.

Canaccord Genuity analyst Whitney Ijem maintains Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Hold and maintains $93 price target.

Canaccord Genuity Maintains Hold on Biomarin Pharmaceutical, Maintains $93 Price Target

Biomarin Pharmaceutical's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NYSE">BMRN</a>) short percent of float has fallen 3.3% since its last report. The company recently reported that it has 6.65 million shares sold short, which is 3.52% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.24 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Biomarin Pharmaceutical Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725977718_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Biomarin Pharmaceutical has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Biomarin Pharmaceutical's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Biomarin Pharmaceutical's peer group average for short interest as a percentage of float is 4.16%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(BMRN) - Analyzing Biomarin Pharmaceutical's Short Interest

Cantor Fitzgerald analyst Olivia Brayer reiterates Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Overweight and maintains $110 price target.

Reiteration

Cantor Fitzgerald Reiterates Overweight on Biomarin Pharmaceutical, Maintains $110 Price Target

Federal regulators are grappling with a significant backlog of factory inspections for drug manufacturing, with many facilities not reviewed since before the pandemic.
An analysis by The Associated Press of FDA data revealed that approximately 42% of the 4,700 registered plants have not undergone FDA surveillance inspections since 2019.
These facilities produce crucial medicines such as antibiotics, blood thinners, and cancer therapies, raising concerns over potential contamination and quality issues.
An AP analysis reveals that approximately 2,000 pharmaceutical manufacturers have not undergone FDA surveillance inspections since before the pandemic. This oversight raises potential contamination risks and other safety issues in medications.
A scholar from Duke University expressed concerns about generic drugmakers reducing costs at the expense of quality, which remains unchecked without proper inspections in an ABC News report.
Tainted medications, like the 2022 incident involving antibiotic-resistant bacteria in eyedrops from an Indian factory, underscore the risks of insufficient oversight.
These factories, particularly in India and China, are critical suppliers of low-cost prescription ingredients in the U.S.
Despite the challenges, FDA Associate Commissioner Michael Rogers <a target="_blank" href="https://abcnews.go.com/Health/wireStory/2000-drug-manufacturing-plants-overdue-fda-inspections-after-113414456" rel="noreferrer noopener">asserted</a> that the FDA is the world&#8217;s most stringent drug regulator. However, he acknowledged that inspection rates are still nearly 40% lower than pre-COVID levels, with no set timeline for clearing the backlog.
The situation is exacerbated by staffing challenges, with many experienced inspectors leaving for more flexible job opportunities.
Internationally, the FDA has been using video and online tools for preliminary assessments, but these do not substitute for physical inspections.
The Government Accountability Office has consistently marked this area as high-risk, signaling that more proactive measures are necessary. In the meantime, the FDA focuses on a risk-based approach to prioritize inspections that pose the greatest public health risk.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40750262/mpox-vaccines-challenges-persist-as-congo-receives-first-batch-of-doses-almost-2-years-after-it-d" target="_blank" rel="noreferrer noopener">Mpox Vaccines: Challenges Persist as Congo Receives First Batch Of Doses Almost 2 Years After It Declared Epidemic</a>.</li>
</ul>
Photo via Shutterstock

Government

Regulations

UTHR

FDA Battles Backlog of Drug Factory Inspections Since COVID-19

BioMarin Pharmaceuticals shares are trading lower after Truist Securities lowered its price target on the stock from $140 to $118.

JP Morgan analyst Jessica Fye maintains Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Overweight and raises the price target from $111 to $120.

JP Morgan Maintains Overweight on Biomarin Pharmaceutical, Raises Price Target to $120

RBC Capital analyst Luca Issi reiterates Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Sector Perform and maintains $100 price target.

RBC Capital Reiterates Sector Perform on Biomarin Pharmaceutical, Maintains $100 Price Target

In a report released today, George Farmer from Scotiabank maintained a Hold rating on BioMarin Pharmaceutical (BMRN – Research Report), with a pric...

BioMarin Pharmaceutical (BMRN) Gets a Hold from Scotiabank

In a report released today, Cory Kasimov from Evercore ISI maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), with a pric...

BioMarin Pharmaceutical (BMRN) Gets a Buy from Evercore ISI

BioMarin Pharmaceutical: A Volatile But Growing Trajectory

Ascendis Challenges BioMarin, But Market Response Seems Excessive

Analyst Whitney Ijem of Canaccord Genuity maintained a Hold rating on BioMarin Pharmaceutical (BMRN – Research Report), retaining the price target ...

Hold Rating on BioMarin Pharmaceutical Amid Competitive Dynamics and Market Penetration Nuances for Voxzogo

Barclays analyst Gena Wang maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report) today and set a price target of $110.00. The...

Barclays Remains a Buy on BioMarin Pharmaceutical (BMRN)

Citi analyst David Lebowitz has maintained their neutral stance on BMRN stock, giving a Hold rating on September 17. David Lebowitz has given his H...

Hold Rating on BioMarin Amid Market Pressures and Steady Therapeutic Leadership

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new B...

3 Best Stocks to Buy Now, 9/19/2024, According to Top Analysts

Catalyst Watch: Spotlight on Micron, Southwest Airlines, and FOMC speakers

Wall Street Breakfast: The Week Ahead

AERG

ALXO

AZUL

BIRK

BRZE

COST

CRWD

ETON

GRDN

HUBS

IART

IMRX

INTU

LGCY

LUNR

MPAA

NBIX

NXST

PGHL

SFIX

TALO

TURB

VERV

VSTO

ZETA

Press Releases

U.S. Food and Drug Administration Approves BioMarin's BRINEURA® (cerliponase alfa) for Children Under 3 Years with CLN2 Disease

BioMarin Announces Updated Strategy for ROCTAVIAN® to Focus on U.S., Germany and Italy

Earnings

BioMarin Announces 20% Y/Y Total Revenue Growth in the Second Quarter and Increase in Full-year 2024 Guidance

BioMarin to Host 2024 Investor Day on September 4th in New York

BioMarin Announces New R&D and Business Development Leadership

BioMarin to Present at the 22nd Annual Morgan Stanley Global Healthcare Conference on Thursday, September 5 at 7:45 AM PT / 10:45 AM ET in New York, NY

BioMarin to Host Investor Day Today at 10:30 a.m. Eastern Time

BioMarin Holds Investor Day; Provides New Corporate Strategy and Introduces 2027 Financial Guidance

Junior Biotech Utilizes AI To Shorten Drug Discovery Timelines, Ultimately Saving Lives

BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® (vosoritide) on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia at 2024 International Skeletal Dysplasia Society Meeting

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Biomarin Pharmaceutical

Biomarin Pharmaceutical (BMRN) Forecast

Biomarin Pharmaceutical (NASDAQ:BMRN) Stock, Quote.Headers.trade-ideas